Approval of Reblozyl is based on head-to-head, pivotal Phase 3 COMMANDS study, in which Reblozyl nearly doubled the percentage of patients achieving transfusion independence and hemoglobin increase,.
Bristol-Myers Squibb (BMY) European Commission Expands Approval of Reblozyl streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
European Commission Expands Approval of Bristol Myers Squibb s Reblozyl (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS) finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
FDA approves Merck's Winrevair for PAH treatment. First-in-class therapy to enhance exercise capacity, improve WHO FC, and reduce clinical worsening. Available in select U.S. pharmacies by April. Pricing details revealed.
Sotatercept-csrk is the first approved activin signaling inhibitor therapy for pulmonary arterial hypertension, which represents a new class of therapy.